| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer |
|
Medicine details |
|
| Medicine name | encorafenib (Braftovi®) |
| Formulation | 50mg, 75 mg hard capsules |
| Reference number | 4014 |
| Indication | In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy |
| Company | Pierre Fabre Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/07/2019 |
| NICE guidance | |
| Commercial arrangement | PAS |